

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number  
**WO 02/32507 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 17/06**,  
29/00

(21) International Application Number: PCT/SE01/02265

(22) International Filing Date: 16 October 2001 (16.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0003828-1 20 October 2000 (20.10.2000) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BONNERT, Roger** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). **WALTERS, Iain** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/32507 A1

(54) Title: 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES

(57) Abstract: Pteridine compounds of formula (I) in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as specified in the claims, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases such as psoriasis, rheumatoid arthritis, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels (diabetic retinopathy) and COPD. The compounds are ligands for chemokine receptors and medical indications mentioned in the description include: diseases of the respiratory tract (COPDD, asthma, bronchitis, rhinitis, fibroid lung, pneumonia, etc.), diseases of the bones and joints (arthritis, etc.), skin-diseases (psoriasis, etc), diseases of the gastrointestinal tract, diseases in other tissues and systemic disease (multiple sclerosis, atherosclerosis, AIDS, type 1 diabetes, leprosy, sepsis, etc.), allograft rejection, cancers, cystic fibrosis, stroke, burn wounds, skin ulcers, reproductive disease and more.

7-Amino-2-alkylthiopteridin-4-yl-amines for the treatment  
of Chemokine-related diseases.

The present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and  
5 their use in therapy.


Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted  
10 molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

15 The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but  
20 not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies  
25 of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4 and CX3CR1. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

30 In accordance with the present invention, there is therefore provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



5 in which

$R^1$  represents a  $C_3$ - $C_7$  carbocyclic,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl group, each of the groups being optionally substituted by one or more substituent groups independently selected from halogen atoms,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$  or an aryl or heteroaryl group, both of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_1$ - $C_6$  alkyl or trifluoromethyl groups;

$R^2$  and  $R^3$  each independently represent a hydrogen atom, or a  $C_3$ - $C_7$  carbocyclic,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from:

- (a) halogen atoms,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ;
- (b) a 3-8 membered ring optionally containing one or more atoms selected from O, S,  $NR^8$  and itself optionally substituted by  $C_1$ - $C_3$ -alkyl or  $OR^4$ ; (remove halogen;)
- (c) an aryl group or heteroaryl group each of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-NR^8COR^9$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_1$ - $C_6$  alkyl and trifluoromethyl groups;

25  $R^4$  represents hydrogen,  $C_1$ - $C_6$  alkyl or a phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,  $-OR^{11}$  and  $-NR^{12}R^{13}$

30  $R^5$  and  $R^6$  independently represent a hydrogen atom or a  $C_1$ - $C_6$  alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups

independently selected from halogen atoms, phenyl, -OR<sup>14</sup> and -NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -SONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup>

or

R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4-

- 5 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, -OR<sup>14</sup>, -COOR<sup>14</sup>, -NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -SONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup> or C<sub>1</sub>-C<sub>6</sub> alkyl, itself  
10 optionally substituted by one or more substituents independently selected from halogen atoms and -NR<sup>15</sup>R<sup>16</sup> and -OR<sup>17</sup> groups;

R<sup>10</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl or a phenyl group, the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR<sup>17</sup> and -NR<sup>15</sup>R<sup>16</sup>; and

15

each of R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> independently represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>, alkyl, or a phenyl group.

- In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl  
20 group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Aryl groups include phenyl and naphthyl. Heteroaryl groups include 5- or 6-membered aromatic rings containing one or more heteroatoms selected from N, S, O. Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, thiophene and furan.

- 25 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

- 30 In formula (I) above, the group R<sup>1</sup> represents a C<sub>3</sub>-C<sub>7</sub> carbocyclic, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl group, each of the groups being optionally substituted by one or more substituent groups independently selected from halogen atoms, -OR<sup>4</sup>, -NR<sup>5</sup>R<sup>6</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -COOR<sup>7</sup>, -NR<sup>8</sup>COR<sup>9</sup>, -SR<sup>10</sup>, -SO<sub>2</sub>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup> or an aryl or heteroaryl group, both of which may be optionally substituted by one or more substituents  
35 independently selected from halogen atoms, cyano, nitro, -OR<sup>4</sup>, -NR<sup>5</sup>R<sup>6</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -COOR<sup>7</sup>, -NR<sup>8</sup>COR<sup>9</sup>, -SR<sup>10</sup>, -SO<sub>2</sub>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl or

trifluoromethyl groups. Preferably  $R^1$  is a  $CH_2$  group substituted by thienyl, furyl or phenyl, each of which can be optionally substituted by one or more  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy or halogen groups. Particularly advantageous compounds of formula (I) are those in which  $R^1$  represents an optionally substituted benzyl group. More preferably  $R^1$  represents benzyl or benzyl substituted by one or more  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy or halogen atoms. Most preferably  $R^1$  represents benzyl or benzyl substituted by fluoro, chloro, or benzyl di-substituted by fluoro, di-substituted by fluoro and chloro or fluoro and methoxy.

When  $R^2$  and  $R^3$  represent a group substituted by one or more 3-8 membered rings optionally containing one or more atoms selected from O, S or  $NR^8$ , examples of such groups include piperidine, pyrrolidine, piperazine and morpholine.

Preferably one of  $R^2$  and  $R^3$  is hydrogen and the other is  $C_1$ - $C_8$  alkyl substituted by hydroxy and one or more methyl or ethyl groups. More preferably one of  $R^2$  and  $R^3$  is hydrogen and the other is  $CH(CH_3)CH_2OH$ ,  $CH(Et)CH_2OH$ ,  $C(CH_3)_2CH_2OH$  or  $CH(CH_2OH)_2$ . Most preferably one of  $R^2$  and  $R^3$  is hydrogen and the other is  $CH(CH_3)CH_2OH$ . When one of  $R^2$  and  $R^3$  is hydrogen and the other is  $CH(CH_3)CH_2OH$  or  $CH(Et)CH_2OH$  the resulting compounds of formula (I) are preferably in the form of the (R) isomer.

Preferably  $R^4$  is hydrogen.

Particularly preferred compounds of the invention include:

(2R)-2-[[7-amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridiny]amino]-1-propanol, 2-[[7-amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridiny]amino]-1,3-propanediol, 2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridiny]amino]-2-methyl-1-propanol,

(2R)-2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridiny]amino]-1-butanol, 2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridiny]amino]-2-methyl-1,3-propanediol,

(2R)-2-[[7-amino-2-[(phenylmethyl)thio]-4-pteridiny]amino]-1-propanol,

(2R)-2-[[7-amino-2-[[[(2-fluorophenyl)methyl]thio]-4-pteridiny]amino]-1-propanol,

(2R)-2-[[7-amino-2-[[[(3-chloro-4-methoxyphenyl)methyl]thio]-4-pteridiny]amino]-1-propanol,

(2R)-2-[[7-amino-2-[[[(3-chlorophenyl)methyl]thio]-4-pteridiny]amino]-1-propanol,

(2R)-2-[[7-amino-2-[[[(5-methyl-2-furanyl)methyl]thio]-4-pteridiny]amino]-1-propanol,


(2R)-2-[[7-amino-2-[(2-thienylmethyl)thio]-4-pteridiny]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(2-fluoro-4-methoxyphenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(3-chloro-2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

5 and their pharmaceutically acceptable salts and solvates.


According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises heating a compound of formula (II):



(II)

where  $R^1$  is as defined in formula (I) with an amine  $R^2R^3NH$ . The reaction may be carried out in neat amine or in a suitable solvent such as 1-methylimidazole at a temperature  
15 between 0°C and 150°C.


Compounds of formula (II) where  $R^1$  is as defined in formula (I) may be prepared by treatment of compounds of formula (III) where  $R^1$  is as defined in formula (I) with a base such as potassium hydroxide or potassium bicarbonate. The reaction may be carried out in  
20 a solvent such as a mixture of methanol and dichloromethane or NMP at a temperature between 0°C and 100°C.



(III)

Compounds of formula (III) where  $R^1$  is as defined in formula (I) and X is a halogen, may be prepared by treatment of compounds of formula (IV) where  $R^1$  is as defined in formula (I) with bromoacetonitrile in the presence of a suitable base. The reaction may be carried


out in a solvent such as DMSO or dioxan using diisopropylethylamine as the base at a temperature between 0°C and 150°C.



5

Compounds of formula (IV) where  $\text{R}^1$  is as defined in formula (I) may be prepared by treatment of a compound of formula (V) with a compound of formula  $\text{R}^1\text{X}$  where  $\text{R}^1$  is as defined in formula (I) above and X is a leaving group such as bromide in the presence of a base such as potassium hydroxide in a solvent such as methanol at ambient temperature.

10



15 The compound of formula (V) is commercially available.

It will be appreciated by those skilled in the art that in the processes described above the functional groups (e.g. hydroxyl groups) of intermediate compounds may need to be protected by protecting groups. The final stage in the preparation of the compounds of the invention may involve the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

20

Novel intermediate compounds form a further aspect of the invention. In particular compounds of formula (II) are novel and form an aspect of the invention.

25

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, either a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptors, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;



- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- 5 (5) **(other tissues and systemic disease)** multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, Sezary syndrome and idiopathic thrombocytopenia
- 10 pupura; post-operative adhesions, and sepsis.
- (6) **(allograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- 15 (7) Cancers, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma, and tumour metastasis;
- (8) Diseases in which angiogenesis is associated with raised CXCR2 chemokine
- 20 levels (e.g. NSCLC, diabetic retinopathy).
- (9) Cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and other organs.
- 25 (10) Burn wounds & chronic skin ulcers
- (11) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)

30 Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CXC chemokine receptor subfamily, more preferably

35 the target chemokine receptor is the CXCR2 receptor,

Particular conditions which can be treated with the compounds of the invention are psoriasis, rheumatoid arthritis, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels, and COPD. It is preferred that the compounds of the invention are used to treat rheumatoid arthritis.

5

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

10

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

15

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

20

The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CXCR2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

25

The invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

30

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

35

The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active

ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.

The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compounds of the invention are administered orally.

The invention will now be further illustrated by reference to the following examples. In the examples the Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer and the Mass Spectrometry (MS) spectra measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Where necessary, the reactions were performed under an inert atmosphere of either nitrogen or argon. Chromatography was generally performed using Matrex Silica 60<sup>®</sup> (35-70 micron) or Prolabo Silica gel 60<sup>®</sup> (35-70 micron) suitable for flash silica gel chromatography. High pressure liquid chromatography purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000. The abbreviations m.p. and DMSO used in the examples stand for melting point and dimethyl sulphoxide respectively.

**Example 1****(2R)-2-[[7-amino-2-[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**5 **(a) 2,6-bis[[2,3-difluorophenyl)methyl]thio]-4,5-pyrimidinediamine**

To a solution of potassium hydroxide powder (7.72 g) in methanol (250 ml) was added first 5,6-diamino-2,4-pyrimidinedithiol (10.9 g) followed by 2,3-difluorobenzyl bromide (22.5 g). The reaction mixture was stirred for one hour at room temperature then poured into  
10 water (500 ml), giving a brown precipitate. This was isolated by filtration, washing with isopropanol and diethyl ether, to give the subtitled compound as a pale brown solid (15.0 g).

MS (APCI) 427 (M+H, 100%).

15

**(b) [[4-amino-2,6-bis[[2,3-difluorophenyl)methyl]thio]-5-pyrimidinyl]amino] acetonitrile**

A solution of the product of example 1 step a) (5.0 g), diisopropylethylamine (2.8 ml) and  
20 bromoacetonitrile (1.1 ml) in DMSO (50 ml) was heated at 100°C for 5 hours. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a black oil which was purified by silica gel flash column chromatography, eluting with 10:1 dichloromethane:ethyl acetate, to give the subtitled  
25 compound as a pale orange solid (1.6 g).

MS (APCI) 466 (M+H, 100%).

NMR  $\delta$ H (CDCl<sub>3</sub>) 7.95-7.25 (6H, m), 5.15 (2H, br s), 4.45 (2H, s), 4.39 (2H, s), 3.82 (2H, d), 2.78 (1H, t).

30

**(c) 2,4-bis[[2,3-difluorophenyl)methyl]thio]-7-pteridinamine**

A solution of the product from example 1 step b) (1.35 g) and potassium hydroxide (114 mg) in methanol (50 ml) and dichloromethane (20 ml) was stirred at room temperature for  
35 24 hours. After evaporation *in vacuo*, the residue was purified by silica gel flash column

chromatography, eluting with 5:1 dichloromethane:ethyl acetate, to give the subtitled compound as a pale yellow solid (0.37 g).

MS (APCI) 463 (M+H).

5 NMR  $\delta$ H ( $d_6$ -DMSO) 8.13 (1H, s), 8.01 (2H, br s), 7.42-7.28 (4H, m), 7.19-7.11 (2H, m), 4.52 (2H, s), 4.49 (2H, s).

**(d) (2R)-2-[[7-amino-2-[[2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

10

A solution of the product from example 1 step c) (0.2 g) in D-alaninol (2 ml) was heated at 120°C for 30 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a brown oil which was purified by  
15 silica gel flash column chromatography, eluting with 200:10:1 dichloromethane:methanol:880 ammonia solution, to give the title compound as a pale brown solid (0.08 g).

m.p. 211-213°C

20 MS (APCI) 379 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.62 (1H, d), 7.43 (2H, s), 7.40 (1H, m), 7.34 (1H, m), 7.13 (1H, m), 4.82 (1H, t), 4.45 (2H, s), 4.25 (1H, m), 3.48 (2H, m), 1.15 (3H, d).

**Example 2**

25

**2-[[7-amino-2-[[2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1,3-propanediol**

A solution of the product from example 1, step (c) (0.12 g) and serinol (330 mg) in 1-methylimidazole (1 ml) was heated at 130°C for 90 minutes. After cooling, the reaction  
30 mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a brown solid which was purified by silica gel flash column chromatography, eluting with 200:20:1 dichloromethane:methanol:880 ammonia solution, to give the title compound as a pale brown solid (0.02 g).

35

m.p. 251-253°C

MS (APCI) 395 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.96 (1H, s), 7.46 (2H, s), 7.41 (1H, m), 7.30 (1H, m), 7.14 (1H, m), 4.80 (2H, t), 4.46 (2H, s), 4.20 (1H, m), 3.57 (4H, m).

5 **Example 3**

**2-[[7-Amino-2-[[2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-2-methyl-1-propanol**

10 A solution of the product from example 1, step (c) (0.25 g) in 2-amino-2-methylpropanol (2.5 ml) was heated in a microwave at 150°C for 45 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a brown oil which was purified by silica gel flash column chromatography, eluting with  
15 100:7 dichloromethane:methanol: and reverse phase HPLC to give the title compound as an off white solid (0.034 g).

m.p. 226-229°C

MS (APCI) 393 (M+H, 100%).

20 NMR  $\delta$ H ( $d_6$ -DMSO) 7.94 (1H, s), 7.46 (2H, s), 7.40 (1H, m), 7.33 (1H, m), 7.16 (2H, m), 5.21 (1H, t), 4.46 (2H, s), 3.48 (2H, m), 1.36 (3H, d).

**Example 4**

25 **(2R)-2-[[7-Amino-2-[[2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-butanol**

A solution of the product from example 1, step (c) (0.25 g) and R-2-aminobutanol (0.24 ml) in N-methylimidazole (1 ml) was heated in a microwave at 150°C for 30 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated  
30 aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a brown oil which was purified by silica gel flash column chromatography, eluting with 100:5 dichloromethane:methanol: and reverse phase HPLC to give the title compound as an off white solid (0.033 g).

35 m.p. 185-189°C

MS (APCI) 393 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.96 (1H, s), 7.56 (1H, d), 7.40 (3H, m), 7.32 (1H, m), 7.14 (1H, m), 4.77 (1H, t), 4.44 (2H, dd), 4.11 (1H, m), 3.49 (2H, dm), 1.60 (2H, dm), 0.83 (3H, t)

### Example 5

#### 2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-2-methyl-1,3-propanediol

A solution of the product from example 1, step (c) (0.25 g) and 2-amino-2-methyl-1,3-propanediol (0.28ml) in N-methylimidazole (1ml) was heated in a microwave at 160°C for 95 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a brown oil which was purified by silica gel flash column chromatography, eluting with 10:1 dichloromethane:methanol to give the title compound as a pale brown solid (0.031 g).

m.p. 220-227°C

MS (APCI) 409 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.56 (2H, s), 7.31 (2H, m), 7.21 (1H, s), 7.15 (1H, m), 5.01 (2H, t), 4.45 (2H, s), 3.67, 3.56 (2H, 2xm), 1.32 (3H, s).

### Example 6

#### (2R)-2-[[7-amino-2-[(phenylmethyl)thio]-4-pteridinyl]amino]-1-propanol

##### (a) 2,6-bis[(phenylmethyl)]thio]-4,5-pyrimidinediamine

Prepared by the method of example 1, step (a), using benzyl bromide

MS (APCI) 355 (M+H, 100%).

##### (b) [[4-amino-2,6-bis[(phenylmethyl)thio]-5-pyrimidinyl]amino] acetonitrile

Prepared by the method of example 1, step (b), using the product from example 6, step (a)

MS (APCI) 394 (M+H, 100%).

**(c) 2,4-bis[(phenylmethyl)thio]-7-pteridinamine**

Prepared by the method of example 1, step (c), using the product from example 6, step (b)

MS (APCI) 390 (M+H, 100%).

**(d) (2R)-2-[[7-amino-2-[(phenylmethyl)thio]-4-pteridinyl]amino]-1-propanol**

Prepared by the method of example 1, step (d), using the product from example 6, step (c)

MS (APCI) 343 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.58 (1H, d), 7.45 -7.20 (5H, m), 4.82 (1H, t), 4.83 (1H, t), 4.38 (2H, m), 4.27 (1H, m), 3.54-3.42 (2H, m), 1.16 (3H, d).

**Example 7****(2R)-2-[[7-amino-2-[(2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol****(a) (2R)-2-[(7-amino-2-mercapto-4-pteridinyl)amino]-1-propanol**

To a suspension of the product from example 6, step (d), (300mg) in liquid ammonia (20 ml) was added sodium metal until a consistent blue colour ensued. This was then quenched with ammonium chloride powder. The solvent was allowed to evaporate and the residue taken up into water (20 ml) and the pH adjusted to 5-6 with concentrated hydrochloric acid. The product was then collected by filtration (75 mg).

MS (APCI) 253 (M+H, 100%).

**(b) (2R)-2-[[7-amino-2-[(2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

To a mixture a mixture of the product from example 7, step (a) (75 mg) in DMSO (1 ml) and Hunigs base (0.2 ml) was added 2-fluorobenzylbromide (30  $\mu$ l) and the mixture stirred at room temperature for 30 mins. The mixture was poured into water (10 ml) extracted into ethyl acetate, dried and evaporated to dryness. The residue was then purified by HPLC. The



above procedure was repeated and both yields combined to give the title compound as a white solid (145mg).

MS (APCI) 361 (M+H, 100%).

5 NMR  $\delta$ H ( $d_6$ -DMSO) 7.96 (1H, s), 7.42 (2H, m), 7.34 (2H, s), 7.29 -7.11 (3H, m), 4.83 (1H, t), 4.36 (2H, m), 4.26 (1H, m), 4.05 (2H, m), 1.16 (3H, d).

#### Example 8

10 (2*R*)-2-[[7-amino-2-[[3-chloro-4-methoxyphenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol

Prepared by the method of example 7, step (b), using 3-chloro-4-methoxybenzyl bromide. The product was purified by recrystallisation from acetonitrile.

15

MS (APCI) 407 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, d), 7.58 (1H, d), 7.50 (1H, d), 7.41 (2H, m), 7.05 (1H, d), 4.82 (1H, t), 4.37 (2H, m), 4.27 (1H, m), 3.82 (3H, s), 3.49 (2H, m), 1.16 (3H, d).

#### 20 Example 9

(2*R*)-2-[[7-amino-2-[[3-chlorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol

Prepared by the method of example 7, step (b), using 3-chloro-benzyl bromide.

25

MS (APCI) 377 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, d), 7.62 (1H, d), 7.51 (1H, m), 7.41 (3H, m), 7.31 (2H, m), 4.82 (1H, t), 4.39 (2H, m), 4.26 (1H, m), 3.53- 3.41 (2H, m), 1.16 (3H, d).

#### 30 Example 10

(2*R*)-2-[[7-amino-2-[[5-methyl-2-furanyl)methyl]thio]-4-pteridinyl]amino]-1-propanol

35 (a) (2*R*)-2-[[7-amino-2-[[2,3-difluorophenyl)methyl]sulphonyl]-4-pteridinyl]amino]-1-propanol

To a suspension of the product from Example 1 (0.54 g) in acetonitrile (200 ml) was added a solution of Oxone (5.4 g) in water (200 ml) and the mixture was stirred overnight. After removing the acetonitrile by concentration, the aqueous solution was neutralised with sodium hydroxide solution and extracted with ethyl acetate. The organic extracts were dried over magnesium sulphate, filtered and concentrated to leave the subtitled compound as a brown solid (0.38 g).

MS (ESI) 411 (M+H, 100%).

**(b) (2R)-2-[[7-amino-2-[(5-methyl-2-furanyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

A solution of the product from example 10, step (a) (0.18 g) and 5-methyl-2-furanmethanethiol (75 mg) in anhydrous DMSO (3 ml) was treated with potassium t-butoxide solution in THF (1.0 M, 0.44 ml) and stirred at room temperature for 1 hour. The solution was purified directly by preparative reversed phase HPLC on a Waters 19 x 50 mm Symmetry C8 silica column eluted with 0.1 % aqueous ammonium acetate : acetonitrile (70 : 30) to give an off-white solid that was dried under reduced pressure at 40°C (8 mg).

MS (APCI) 347 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.61 (1H, d), 7.40 (2H, br), 6.18 (1H, m), 5.96 (1H, s), 4.83 (1H, t), 4.37 (2H, s), 4.27 (1H, m), 3.42 - 3.54 (2H, m), 2.22 (3H, s), 1.17 (3H, d).

**Example 11**

**(2R)-2-[[7-amino-2-[(2-thienylmethyl)thio]-4-pteridinyl]amino]-1-propanol**

A solution of the product from Example 10, step (a) (0.18 g) and 2-thienylmercaptan (70 mg) in anhydrous DMSO (3 ml) was treated with potassium t-butoxide solution in THF (1.0 M, 0.44 ml) and stirred at room temperature for 1 hour. The solution was purified directly by preparative reversed phase HPLC on a Waters 19 x 50 mm Symmetry C8 silica column eluted with 0.1 % aqueous ammonium acetate : acetonitrile (70 : 30) to give an off-white solid that was dried under reduced pressure at 40 ° (20 mg).

MS (APCI) 349 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.96 (1H, s), 7.62 (1H, d), 7.42 (2H, br), 7.34 (1H, m), 7.08 (1H, m), 6.92 (1H, m), 4.83 (1H, t), 4.59 (2H, m), 4.29 (1H, m), 3.42 - 3.54 (2H, m), 1.17 (3H, d).

5

### Example 12

**(2R)-2-[[7-amino-2-[(2-fluoro-4-methoxyphenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

10

Thionyl chloride (0.19 ml) was added to an ice-cold solution of 2-fluoro-4-methoxybenzenemethanol (0.188 g) in dichloromethane (10 ml) and the resulting solution was stirred for 1 hour then concentrated. The residue was dissolved in DMSO (3 ml) and *N,N*-diisopropylethylamine (0.35 ml) and the product from example 7, step (a) (0.252 g) were added. After stirring at room temperature overnight, the mixture was purified directly by preparative reversed phase HPLC on a Waters 19 x 50 mm Symmetry C8 silica column eluted with 0.1 % aqueous ammonium acetate : acetonitrile (65 : 35) to give a pale brown powder that was dried under reduced pressure at 40 ° (0.173 g).

20

MS (APCI) 391 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.59 (1H, d), 7.47 (1H, t), 7.41 (2H, br), 6.82 (1H, m), 6.72 (1H, m), 4.82 (1H, t), 4.33 (2H, s), 4.22 - 4.29 (1H, m), 3.74 (3H, s), 3.41 - 3.55 (2H, m), 1.17 (3H, d).

25

### Example 13

**(2R)-2-[[7-amino-2-[(3-chloro-2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

30

**(a) 2,6-bis[[3-chloro-2-fluorophenyl)methyl]thio]-4,5-pyrimidinediamine**

To a solution of potassium hydroxide powder (2.5 g) in methanol (80 ml) was added first 5,6-diamino-2,4-pyrimidinedithiol (3.6 g) followed by 3-chloro-2-fluorobenzyl bromide (6.3 g). The reaction mixture was stirred for one hour at room temperature then poured into water (180 ml), giving a brown precipitate. This was isolated by filtration, washing with

35

isopropyl alcohol and diethyl ether, to give the subtitled compound as a pale brown solid (5.4 g).

MS (APCI+ve) 459/461/463 (M+H, 100%).

5  
**(b) [[4-amino-2,6-bis[[[(3-chloro-2-fluorophenyl)methyl]thio]-5-pyrimidinyl]amino]acetonitrile**

To a solution of the product of example 13, step (a) (4.2 g) and diisopropylethylamine (1.2 ml) in dioxan (40 ml) was added bromoacetonitrile (1.2 g) and the mixture heated at 100°C for 23 hours. After cooling, the red reaction solution was adsorbed onto silica and purified by silica gel flash column chromatography, eluting with dichloromethane then 95:5 dichloromethane:ethyl acetate, to give the subtitled compound as a pale orange solid (3.1 g).

MS (APCI+ve) 498 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.38-7.16 (6H, m), 6.97 (2H, br s), 4.42 (1H, s), 4.34 (4H, s), 3.86 (2H, d).

20  
**(c) 2,4-bis[[[(3-chloro-2-fluorophenyl)methyl]thio]-7-pteridinamine**

A solution of the product from example 13, step (b) (1.4 g) and potassium hydroxide (110 mg) in methanol (80 ml) and dichloromethane (120 ml) was stirred at room temperature for 24 hours. After evaporation *in vacuo*, the residue rendered the subtitled compound as a pale yellow solid (1.4 g).

MS (APCI+ve) 496/498/500 (M+H).

NMR  $\delta$ H ( $d_6$ -DMSO) 8.13 (1H, s), 8.02 (2H, br s), 7.46-7.17 (6H, m), 4.44 (4H, s).

30  
**(d) (2R)-2-[[7-amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol**

A solution of the product from example 13, step (c) (1.0 g) in D-alaninol (10 ml) was heated at 120°C for 40 minutes. After cooling, the reaction mixture was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic phase was dried over magnesium sulphate, filtered and evaporated to give a light brown solid which

was purified by silica gel flash column chromatography, eluting with dichloromethane then 30:1 then 20:1 dichloromethane:methanol, to give the title compound as a pale brown solid (0.25 g).

5 m.p. 224-226°C

MS (APCI) 394/396 (M+H, 100%).

NMR  $\delta$ H ( $d_6$ -DMSO) 7.95 (1H, s), 7.61 (1H, t), 7.56 (1H, s), 7.45 (3H, m), 7.16 (1H, t), 4.83 (1H, t), 4.34 (2H, s), 4.23 (1H, m), 3.50 (2H, m), 1.15 (3H, d).

## 10 Pharmacological Data

### Ligand Binding Assay

[<sup>125</sup>I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of  
15 hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* **267** pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared  
20 using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease  
25 inhibitors (1mM phenyl methyl sulphonyl fluoride, 2 $\mu$ g/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5 $\mu$ g/ml leupeptin and 100 $\mu$ g/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented  
30 with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH<sub>2</sub>PO<sub>4</sub>), 0.1%(w/v) gelatin and 10%(v/v) glycerol.

All assays were performed in a 96-well MultiScreen 0.45 $\mu$ m filtration plates (Millipore, U.K.). Each assay contained ~50pM [<sup>125</sup>I]IL-8 and membranes (equivalent to ~200,000  
35 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a

compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice  
5 with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra  $\gamma$ -counter.

The compounds of formula (I) according to the Examples were found to have IC<sub>50</sub> values  
10 of less than (<) 10 $\mu$ M.

#### **Intracellular Calcium Mobilisation Assay**

Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) *Methods in Enzymology* 287 pp70-72), in storage buffer  
15 [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH<sub>2</sub>PO<sub>4</sub>) supplemented with 5.7mM glucose and 10mM HEPES (pH 7.4)].


The chemokine GRO $\alpha$  (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular  
20 free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990) *Biochem. J.* 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5 $\mu$ M fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v)  
25 bovine serum albumin (BSA), 1.8mM CaCl<sub>2</sub> and 1mM MgCl<sub>2</sub>. The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in DMSO and  
30 added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A<sub>50</sub> concentration of GRO $\alpha$  and the transient increase in fluo-3 fluorescence ( $\lambda_{Ex}$  = 490nm and  $\lambda_{Em}$  = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

35 The compounds of formula (I) according to the Examples were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

## CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:



in which

$R^1$  represents a  $C_3$ - $C_7$  carbocyclic,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl group, each of the groups being optionally substituted by one or more substituent groups independently selected from halogen atoms,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$  or an aryl or heteroaryl group, both of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_1$ - $C_6$  alkyl or trifluoromethyl groups;

$R^2$  and  $R^3$  each independently represent a hydrogen atom, or a  $C_3$ - $C_7$  carbocyclic,  $C_1$ - $C_8$  alkyl,  $C_2$ - $C_6$  alkenyl or  $C_2$ - $C_6$  alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from:

- (a) halogen atoms,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$
- (b) a 3-8 membered ring optionally containing one or more atoms selected from O, S,  $NR^8$  and itself optionally substituted by  $C_1$ - $C_3$ -alkyl or halogen,
- (c) an aryl group or heteroaryl group each of which may be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-NR^8COR^9$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_1$ - $C_6$  alkyl and trifluoromethyl groups;

$R^4$  represents hydrogen,  $C_1$ - $C_6$  alkyl or a phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,  $-OR^{11}$  and  $-NR^{12}R^{13}$

$R^5$  and  $R^6$  independently represent a hydrogen atom or a  $C_1$ - $C_6$  alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,  $-OR^{14}$  and  $-NR^{15}R^{16}$ ,  $-CONR^{15}R^{16}$ ,  
 5  $-NR^{15}COR^{16}$ ,  $-SONR^{15}R^{16}$ ,  $NR^{15}SO_2R^{16}$

or

$R^5$  and  $R^6$  together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted  
 10 by one or more substituent groups independently selected from phenyl,  $-OR^{14}$ ,  $-COOR^{14}$ ,  $-NR^{15}R^{16}$ ,  $-CONR^{15}R^{16}$ ,  $-NR^{15}COR^{16}$ ,  $-SONR^{15}R^{16}$ ,  $NR^{15}SO_2R^{16}$  or  $C_1$ - $C_6$  alkyl, itself optionally substituted by one or more substituents independently selected from halogen atoms and  $-NR^{15}R^{16}$  and  $-OR^{17}$  groups;

15  $R^{10}$  represents a hydrogen atom or a  $C_1$ - $C_6$ -alkyl or a phenyl group, the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl,  $-OR^{17}$  and  $-NR^{15}R^{16}$ ; and

each of  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  independently represents a hydrogen  
 20 atom or a  $C_1$ - $C_6$ , alkyl, or a phenyl group.

2. A compound according to claim 1, wherein  $R^1$  represents an optionally substituted benzyl group.

25 3. A compound according to claim 1 or claim 2, wherein one of  $R^2$  and  $R^3$  is hydrogen and the other is  $C_1$ - $C_8$  alkyl substituted by hydroxy and one or more methyl or ethyl groups.

4. A compound according to any one of claims 1 to 3, wherein  $R^4$  is hydrogen.

30 5. A compound according to claim 1 selected from:

(2*R*)-2-[[7-amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,  
 2-[[7-amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1,3-propanediol,  
 2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-2-methyl-1-  
 propanol,

35 (2*R*)-2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-butanol,



2-[[7-Amino-2-[[[(2,3-difluorophenyl)methyl]thio]-4-pteridinyl]amino]-2-methyl-1,3-propanediol,

(2*R*)-2-[[7-amino-2-[(phenylmethyl)thio]-4-pteridinyl]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

5 (2*R*)-2-[[7-amino-2-[[[(3-chloro-4-methoxyphenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(3-chlorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(5-methyl-2-furanyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

(2*R*)-2-[[7-amino-2-[[[(2-thienylmethyl)thio]-4-pteridinyl]amino]-1-propanol,

10 (2*R*)-2-[[7-amino-2-[[[(2-fluoro-4-methoxyphenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,


(2*R*)-2-[[7-amino-2-[[[(3-chloro-2-fluorophenyl)methyl]thio]-4-pteridinyl]amino]-1-propanol,

and their pharmaceutically acceptable salts and solvates.

15

6. A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:

(a) treating a compound of formula (II):



20

(II)

where  $R^1$  is as defined in formula (I) with with an amine  $R^2R^3NH$  and optionally thereafter forming a pharmaceutically acceptable salt.

25

7. A compound of formula (II) where  $R^1$  is as defined in formula (I).

8. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5

30 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A process for the preparation of a pharmaceutical composition as claimed in claim 8 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5 with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5 for use in therapy.

11. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5 in the manufacture of a medicament for use in therapy.

12. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5.

13. A method according to claim 12 in which the chemokine receptor belongs to the CXC chemokine receptor subfamily.

14. A method according to claim 12 or 13 in which the chemokine receptor is the CXCR2 receptor.

15. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5.

16. A method according to claim 15, wherein the disease is psoriasis, rheumatoid arthritis, a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or COPD.

17. A method according to claim 15, wherein the disease is rheumatoid arthritis.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/02265

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61P 17/06, A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, CHEM.ABS.DATA, EMBASE, WPI DATA, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. Med. Chem., Volume 11, No. 3, 1968, Joseph Weinstock et al: "Pteridines. XII.1 Structure-Activity Relationship of Some Pteridine Diuretics", page 573 - page 579, page 576, table VII --	1
X	GB 1009477 A (SMITH KLINE & FRENCH LABORATORIES), 10 November 1965 (10.11.65), page 3, example 3 --	1
P, X	STN International, File CHEMCATS, CHEMCATS accession no: 2001:1442861, "4,7-Pteridinediamine, 9-phenyl-2- [(phenylmethyl)THIO], CAS registry 343347-55-7, 1 July 2001 --	1-2



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

20 February 2002

22-02-2002

Name and mailing address of the ISA:

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

PER RENSTRÖM/BS

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/02265

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STN International, file CAPLUS, CAPLUS accession no. 2000:76301, document no. 132:98128, Peop.Rep.China: "Antiinflammatory and analgesic capsules containing betamethasone, vitamin B6, dihydrochlorothiazide and triamterene", & CN,A,1180520,19980506  -----	1-17

## International application No.

PCT/SE 01/02265

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1009477 A	10/11/65	US 3164596 A	05/01/65
		US 3182062 A	04/05/65
-----			

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE01/02265

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-17  
because they relate to subject matter not required to be searched by this Authority, namely:  
see next sheet\*
2. ☒ Claims Nos.: 12-14  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
see next sheet\*\*
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

international application No.  
PCT/SE01/02265

\*

Claims 12-17 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

\*\*

The present claims 12-14 have been found to be unsearchable, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out. Specially, the term "a chemokine mediated disease" apparently relates to a very large amount of different diseased and medical states, which do not necessarily have to be defined as chemokine mediated, thus rendering it impossible to perform a search within reasonable time and cost limits.